From the Research
5-Amino-1-methylquinolinium (5-AMQ) is primarily used as a potent inhibitor of Nicotinamide N-methyltransferase (NNMT), an enzyme that plays important roles in cellular metabolism and has been implicated in various diseases including cancer, obesity, and neurodegenerative disorders. The use of 5-AMQ in relation to NNMT is based on its ability to act as a substrate for the enzyme, which methylates it to produce a product that can be easily detected and quantified [ 1 ]. Some key points about 5-AMQ and NNMT include:
- NNMT is overexpressed in select tissues in pathophysiological conditions, making it a clinically relevant target for drug development in several chronic diseases [ 1 ]
- 5-AMQ has been shown to inhibit NNMT activity, which can lead to anti-proliferative effects in cancer cells [ 2 ]
- The inhibition of NNMT by 5-AMQ can also lead to changes in the microbiome, which can have implications for the treatment of metabolic disorders [ 3 ]
- Other studies have reported the development of new bisubstrate inhibitors of NNMT, which can provide insights into the binding mode, affinity, and selectivity of these inhibitors [ 4 ]
- Small molecule inhibitors of NNMT, such as JBSNF-000088, have been shown to reduce MNA levels and drive insulin sensitization, glucose modulation, and body weight reduction in animal models of metabolic disease [ 5(https://doi.org/10.1038/s41598-018-193 erotisch) ] Overall, the use of 5-AMQ in relation to NNMT is an area of ongoing research, with potential implications for the treatment of various diseases.